Meeting the challenges of an emerging pathogen: The Henry Schueler 41&9 foundation international forum on mucormycosis

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 1, 2012, Pages

  Walsh, Thomas J ^a   Bloom, Bruce E ^b   Kontoyiannis, Dimitrios P ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b Partnership for Cures   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; BRAIN INFECTION; DISEASE SEVERITY; GROUPS BY AGE; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE MUCORMYCOSIS; LUNG INFECTION; MORTALITY; MUCORMYCOSIS; NON PROFIT ORGANIZATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHINITIS; SINUSITIS; TAXONOMY;

COMMUNICABLE DISEASES, EMERGING; HUMANS; INTERNATIONAL COOPERATION; MUCORALES; MUCORMYCOSIS;

EID: 84855897249     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir862     Document Type: Article

References (15)

1. Schueler MJ. Into the winter whiteness. Clin Infect Dis 2012;54(Suppl 1): S5-7.
2. Walsh TJ, Roilides E, Rex JH, McGinnis MR. Mucormycosis and entomophthoromycosis. In: Guerrant R, Walker D, Weller P, eds. Tropical infectious diseases. principles, pathogens, and practice. 3rd ed. In press.
3. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycological perspectives. Clin Infect Dis 2012;54(Suppl 1): S8-15.
4. Ibrahim A, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012;54(Suppl 1): S16-22.
5. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54(Suppl 1): S23-34.
6. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53. (Pubitemid 41170352)
7. Lanternier F, Dannaoui E, Morizot G, et al; and the French Mycosis Study Group. A global analysis of mucormycosis in France: the "RetroZygo study" (2005-2007). Clin Infect Dis 2012;54(Suppl 1): S35-43.
8. Rammaert B, Lanternier F, Zahar J-R, et al. Healthcare-associated zygomycosis. Clin Infect Dis 2012;54(Suppl 1): S44-54.
9. Walsh TJ, McGinnis MR, Kontoyiannis DP. Advances in the early laboratory diagnosis ofmucormycosis. Clin Infect Dis 2012;54(Suppl 1): S55-60.
10. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against Zygomycetes. Clin Infect Dis 2012;54(Suppl 1): S61-6.
11. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colonystimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes. J Infect Dis 2005;191:1180-7. (Pubitemid 40404378)
12. Chamilos G, Lewis RE, Hu J, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A 2008;105:9367-72.
13. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis vs.aspergillosis? Clin Infect Dis 2012;54(Suppl 1): S67-72.
14. Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012;54(Suppl 1): S73-8.
15. Kontoyiannis DP, Lewis RE, Lortholary O, et al. Future directions in mucormycosis research. Clin Infect Dis 2012;54(Suppl 1): S79-85.